Prostate Cancer and Prostatic Diseases This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Addressing gaps in healthcare provider knowledge regarding germline testing for prostate cancer through development and testing of a virtual genetics board
Prostate Cancer and Prostatic Diseases, Published online: 03 January 2024; doi:10.1038/s41391-023-00778-9Addressing gaps in healthcare provider knowledge regarding germline testing for prostate cancer through development and testing of a virtual genetics board (Source: Prostate Cancer and Prostatic Diseases)
Source: Prostate Cancer and Prostatic Diseases - January 3, 2024 Category: Urology & Nephrology Authors: Stacy Loeb Heather H. Cheng Channing J. Paller Emily Weg Jennifer Johnson Laura Gross Scott W. Keith Jessica Russo Feighanne Hathaway Adrian Rivera Veda N. Giri Source Type: research

Androgen deprivation therapy for prostate cancer and neurocognitive disorders: a systematic review and meta-analysis
Prostate Cancer and Prostatic Diseases, Published online: 02 January 2024; doi:10.1038/s41391-023-00785-wAndrogen deprivation therapy for prostate cancer and neurocognitive disorders: a systematic review and meta-analysis (Source: Prostate Cancer and Prostatic Diseases)
Source: Prostate Cancer and Prostatic Diseases - January 2, 2024 Category: Urology & Nephrology Authors: David E. Hinojosa-Gonzalez Affan Zafar Gal Saffati Shane Kronstedt Dimitar V. Zlatev Mohit Khera Source Type: research

Avoiding unnecessary biopsy: the combination of PRIMARY score with prostate-specific antigen density for prostate biopsy decision
Prostate Cancer and Prostatic Diseases, Published online: 30 December 2023; doi:10.1038/s41391-023-00782-zAvoiding unnecessary biopsy: the combination of PRIMARY score with prostate-specific antigen density for prostate biopsy decision (Source: Prostate Cancer and Prostatic Diseases)
Source: Prostate Cancer and Prostatic Diseases - December 30, 2023 Category: Urology & Nephrology Authors: Shikuan Guo Jingliang Zhang Yingmei Wang Jianhua Jiao Zeyu Li Chaochao Cui Jian Chen Wenhui Yang Shuaijun Ma Peng Wu Yuming Jing Weihong Wen Fei Kang Jing Wang Weijun Qin Source Type: research

Prevalence of lower urinary tract symptoms in taxi drivers: a cross-sectional web-based survey
Prostate Cancer and Prostatic Diseases, Published online: 30 December 2023; doi:10.1038/s41391-023-00777-wPrevalence of lower urinary tract symptoms in taxi drivers: a cross-sectional web-based survey (Source: Prostate Cancer and Prostatic Diseases)
Source: Prostate Cancer and Prostatic Diseases - December 30, 2023 Category: Urology & Nephrology Authors: Vincenzo Li Marzi Stefania Musco Riccardo Lombardo Antonio Cicione Luca Gemma Simone Morselli Maria Lucia Gallo Sergio Serni Riccardo Campi Cosimo De Nunzio Simone Albisinni Sabrina De Cillis Paolo Geretto Laura Pellizzari Gianluca Sampogna Lorenzo Vacca Source Type: research

Which protocol for prostate biopsies in patients with a positive MRI? Interest of systematic biopsies by sectors
Prostate Cancer and Prostatic Diseases, Published online: 19 December 2023; doi:10.1038/s41391-023-00770-3Which protocol for prostate biopsies in patients with a positive MRI? Interest of systematic biopsies by sectors (Source: Prostate Cancer and Prostatic Diseases)
Source: Prostate Cancer and Prostatic Diseases - December 19, 2023 Category: Urology & Nephrology Authors: A. Zambon T-A. Nguyen A. Fourcade T. Segalen K. Saout C. Deruelle V. Joulin V. Tissot L. Doucet G. Fournier A. Valeri Source Type: research

Concerns regarding prostate cancer screening guidelines in minority populations
Prostate Cancer and Prostatic Diseases, Published online: 19 December 2023; doi:10.1038/s41391-023-00765-0Prostate-Specific Antigen (PSA) is a first-line recommended serum biomarker used for prostate cancer (PCa) screening. However, this test has critical limitations in specificity within the gray zone of PSA from 4–10 ng/ml. The low specificity for clinically significant Gleason grade group 2–5 (GG2-5) PCa leads to unnecessary negative biopsies, over-detection of indolent cancers, and over-treatment, especially in Black men with favorable risk PCa. The urological community relies on secondary screening tools to augm...
Source: Prostate Cancer and Prostatic Diseases - December 19, 2023 Category: Urology & Nephrology Authors: Jamila Sweis Bernice Ofori Adam B. Murphy Source Type: research

Molecular mechanisms underpinning favourable physiological adaptations to exercise prehabilitation for urological cancer surgery
Prostate Cancer and Prostatic Diseases, Published online: 18 December 2023; doi:10.1038/s41391-023-00774-zMolecular mechanisms underpinning favourable physiological adaptations to exercise prehabilitation for urological cancer surgery (Source: Prostate Cancer and Prostatic Diseases)
Source: Prostate Cancer and Prostatic Diseases - December 18, 2023 Category: Urology & Nephrology Authors: James E. M. Blackwell Nima Gharahdaghi Colleen S. Deane Matthew S. Brook John P. Williams Jonathan N. Lund Philip J. Atherton Ken Smith Daniel J. Wilkinson Bethan E. Phillips Source Type: research

Safety profile of darolutamide versus placebo: a systematic review and meta-analysis
Prostate Cancer and Prostatic Diseases, Published online: 14 December 2023; doi:10.1038/s41391-023-00775-ySafety profile of darolutamide versus placebo: a systematic review and meta-analysis (Source: Prostate Cancer and Prostatic Diseases)
Source: Prostate Cancer and Prostatic Diseases - December 14, 2023 Category: Urology & Nephrology Authors: Fabio Turco Silke Gillessen Giorgio Treglia Karim Fizazi Matthew R. Smith Bertrand Tombal Richard Cathomas Consuelo Buttigliero Massimo Di Maio Marcello Tucci Ursula M. Vogl Source Type: research

Association of prostate cancer with human papillomavirus infections: a case-control study
Prostate Cancer and Prostatic Diseases, Published online: 14 December 2023; doi:10.1038/s41391-023-00772-1Association of prostate cancer with human papillomavirus infections: a case-control study (Source: Prostate Cancer and Prostatic Diseases)
Source: Prostate Cancer and Prostatic Diseases - December 14, 2023 Category: Urology & Nephrology Authors: Shuo-Han Yin Shiu-Dong Chung Shih-Han Hung Tsai-Ching Liu Herng-Ching Lin Source Type: research

From BPH to male LUTS: a 20-year journey of the EAU guidelines
Prostate Cancer and Prostatic Diseases, Published online: 13 December 2023; doi:10.1038/s41391-023-00773-0From BPH to male LUTS: a 20-year journey of the EAU guidelines (Source: Prostate Cancer and Prostatic Diseases)
Source: Prostate Cancer and Prostatic Diseases - December 13, 2023 Category: Urology & Nephrology Authors: Steven A. Kaplan Source Type: research

Feasibility of a novel wearable thermal device for management of bothersome hot flashes in patients with prostate cancer
Prostate Cancer and Prostatic Diseases, Published online: 13 December 2023; doi:10.1038/s41391-023-00771-2Feasibility of a novel wearable thermal device for management of bothersome hot flashes in patients with prostate cancer (Source: Prostate Cancer and Prostatic Diseases)
Source: Prostate Cancer and Prostatic Diseases - December 13, 2023 Category: Urology & Nephrology Authors: Pamela Peeke Sonja K. Billes Andrew Vetter Nader Naghavi Diana Le Matthew Smith Alicia K. Morgans Source Type: research

The effects of glycemic index on prostate cancer progression in a xenograft mouse model
Prostate Cancer and Prostatic Diseases, Published online: 11 December 2023; doi:10.1038/s41391-023-00769-wThe effects of glycemic index on prostate cancer progression in a xenograft mouse model (Source: Prostate Cancer and Prostatic Diseases)
Source: Prostate Cancer and Prostatic Diseases - December 11, 2023 Category: Urology & Nephrology Authors: Gloria Cecilia Galv án Everardo Macias Sergio Sanders Adela Ramirez-Torres Shannon Stock Sungyong You Celine E. Riera Patrick Tamukong Stephanie A. Smith-Warner Jeanine M. Genkinger Daniel J. Luthringer Michael R. Freeman Stephen J. Freedland Source Type: research

Correction: Retreatment rates and postprocedural complications are higher than expected after BPH surgeries: a US healthcare claims and utilization study
Prostate Cancer and Prostatic Diseases, Published online: 11 December 2023; doi:10.1038/s41391-023-00756-1Correction: Retreatment rates and postprocedural complications are higher than expected after BPH surgeries: a US healthcare claims and utilization study (Source: Prostate Cancer and Prostatic Diseases)
Source: Prostate Cancer and Prostatic Diseases - December 11, 2023 Category: Urology & Nephrology Authors: Steve Kaplan Ronald P. Kaufman Jr Thomas Mueller Dean Elterman Bilal Chughtai Daniel Rukstalis Henry Woo Claus Roehrborn Source Type: research

High-risk biochemical recurrence of locally treated prostate cancer after EMBARK. An end to decades of conventional wisdom?
Prostate Cancer and Prostatic Diseases, Published online: 08 December 2023; doi:10.1038/s41391-023-00767-yHigh-risk biochemical recurrence of locally treated prostate cancer after EMBARK. An end to decades of conventional wisdom? (Source: Prostate Cancer and Prostatic Diseases)
Source: Prostate Cancer and Prostatic Diseases - December 8, 2023 Category: Urology & Nephrology Authors: V érane Achard Bertrand Tombal Source Type: research

Real-world prevalence of homologous recombination repair mutations in advanced prostate cancer: an analysis of two clinico-genomic databases
Prostate Cancer and Prostatic Diseases, Published online: 06 December 2023; doi:10.1038/s41391-023-00764-1Real-world prevalence of homologous recombination repair mutations in advanced prostate cancer: an analysis of two clinico-genomic databases (Source: Prostate Cancer and Prostatic Diseases)
Source: Prostate Cancer and Prostatic Diseases - December 6, 2023 Category: Urology & Nephrology Authors: Irene M. Shui Mehmet Burcu Changxia Shao Cai Chen Chi-Yin Liao Shan Jiang Razvan Cristescu Ravi B. Parikh Source Type: research